US20160122714A1 - Serum-free medium containing pdgf for ds cells - Google Patents

Serum-free medium containing pdgf for ds cells Download PDF

Info

Publication number
US20160122714A1
US20160122714A1 US14/897,312 US201414897312A US2016122714A1 US 20160122714 A1 US20160122714 A1 US 20160122714A1 US 201414897312 A US201414897312 A US 201414897312A US 2016122714 A1 US2016122714 A1 US 2016122714A1
Authority
US
United States
Prior art keywords
cells
serum
pdgf
medium
free medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/897,312
Other languages
English (en)
Inventor
Haruyo Yamanishi
Tsutomu Soma
Yuzo Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Assigned to SHISEIDO COMPANY, LTD. reassignment SHISEIDO COMPANY, LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SOMA, TSUTOMU, YAMANISHI, HARUYO, YOSHIDA, YUZO
Publication of US20160122714A1 publication Critical patent/US20160122714A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0627—Hair cells
    • C12N5/0628—Hair stem cells; Hair progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]

Definitions

  • the present invention relates to a serum-free medium for culturing of DS cells, comprising platelet-derived growth factor (PDGF), and to a method for culturing of dermal sheath (DS) cells, using serum-free medium comprising PDGF.
  • PDGF platelet-derived growth factor
  • Hair follicles are exceptional organs that repeat self-regeneration in the mature body essentially throughout the entire lifetime. Elucidating the mechanism of this self-regeneration is expected to lead to highly demanded clinical applications, such as alopecia treatment by transplantation of tissue or cells, or construction of near-natural, highly functional skin sheets that include hair follicles and sebaceous glands.
  • alopecia treatment by transplantation of tissue or cells
  • follicular epithelial stem cells epithelial stem cells
  • follicular epithelial stem cells epithelial stem cells
  • Hair papilla cells perform the role of “control towers”, that is, of sending activation signals to follicular epithelial stem cells for self-regeneration of hair follicles, and have been found to be essential cells, together with follicular epithelial stem cells, in the hair follicle reconstitution evaluation system (Kishimoto et al., Proc. Natl. Acad. Sci. USA (1999), Vol. 96, pp. 7336-7341; NPL 1).
  • Hair papilla or dermal papilla, DP
  • DS dermal sheath
  • Hair follicles are both composed of mesenchymal cell groups, unlike the epithelial cells forming the major portions of the hair follicles.
  • DS cells play an important role in hair follicle formation
  • the action mechanism has not yet been fully elucidated. It is necessary to obtain large amounts of DS cells in order to shed light on the action mechanism for hair follicle formation, but because of the small number of cells that can be harvested from biological tissue, it becomes necessary to accomplish efficient growth by in vitro culturing of the cells.
  • serum-added medium that promotes cell growth and binding to the culture vessel, but since antigenic variation and pathogenic contamination can potentially occur under such conditions, and variation may arise in the experimental results due to unidentifiable trace components in the serum, it is unsuitable for clinical applications for regenerative medicine or for drug development or toxicity test applications.
  • the present inventors have acquired the surprising knowledge that it is possible to significantly grow DS cells by culturing in serum-free medium containing added PDGF, and particularly PDGF-BB.
  • the present invention therefore encompasses the following.
  • a serum-free medium for culturing of dermal sheath (DS) cells comprising platelet-derived growth factor (PDGF).
  • DS dermal sheath
  • PDGF platelet-derived growth factor
  • DS dermal sheath
  • PDGF platelet-derived growth factor
  • the serum-free medium of the invention allows efficient culturing of DS cells suitable for clinical applications in regenerative medicine or applications for drug development or toxicity testing.
  • FIG. 1 is a photomicrograph of human DS cells cultured using 1) HFDM-1( ⁇ ) medium, 2) HFDM-1(+) medium, 3) PDGF-AA (10 ng/ml)-dissolved HFDM-1( ⁇ ) medium and 4) PDGF-BB (10 ng/ml)-dissolved HFDM-1( ⁇ ) medium, as serum-free media, on days 2 and 10.
  • FIG. 2 is a graph showing changes in cell counts of human DS cells cultured using 1) HFDM-1( ⁇ ) medium, 2) HFDM-1(+) medium, 3) PDGF-AA (10 ng/ml)-dissolved HFDM-1( ⁇ ) medium and 4) PDGF-BB (10 ng/ml)-dissolved HFDM-1( ⁇ ) medium, as serum-free media (days 2, 5 and 10).
  • FIG. 3 is a photomicrograph of human DS cells cultured using 1) StemProSFM CTS (sup+, Life Technologies), 2) PDGF-BB (10 ng/ml)-dissolved StemProSFM CTS (sup+, Life Technologies), 3) Mosaic hMSC SF Culture Medium (sup+, BD) and 4) PDGF-BB (10 ng/ml)-dissolved Mosaic hMSC SF Culture Medium (sup+, BD), as serum-free medium, on days 2 and 7.
  • FIG. 4 is a graph showing changes in cell counts of human DS cells cultured using 1) StemProSFM CTS (sup+, Life Technologies), 2) PDGF-BB (10 ng/ml)-dissolved StemProSFM CTS (sup+, Life Technologies), 3) Mosaic hMSC SF Culture Medium (sup+, BD) and 4) PDGF-BB (10 ng/ml)-dissolved Mosaic hMSC SF Culture Medium (sup+, BD), as serum-free media (days 2 and 7).
  • FIG. 5 is a photomicrograph of human DS cells cultured using 1) HFDM-1( ⁇ ) medium, 2) HFDM-1(+) medium, 3) PDGF-AA (10 ng/ml)-dissolved HFDM-1( ⁇ ) medium and 4) PDGF-BB (10 ng/ml)-dissolved HFDM-1( ⁇ ) medium, as serum-free media, on days 2 and 7.
  • FIG. 6 is a graph showing changes in cell counts of human DS cells cultured using 1) HFDM-1( ⁇ ) medium, 2) HFDM-1(+) medium, 3) PDGF-AA (10 ng/ml)-dissolved HFDM-1( ⁇ ) medium and 4) PDGF-BB (10 ng/ml)-dissolved HFDM-1( ⁇ ) medium, as serum-free media (days 2, 4 and 7).
  • FIG. 7 is a photomicrograph of human DS cells cultured using 1) StemProSFM CTS (sup ⁇ , Life Technologies), 2) PDGF-BB (10 ng/ml)-dissolved StemProSFM CTS (sup ⁇ , Life Technologies), 3) StemProSFM CTS (sup+, Life Technologies) and 4) PDGF-BB (10 ng/ml)-dissolved StemProSFM CTS (sup+, Life Technologies), as serum-free media, on days 2 and 7.
  • FIG. 8 is a graph showing changes in cell counts of human DS cells cultured using 1) StemProSFM CTS (sup ⁇ , Life Technologies), 2) PDGF-BB (10 ng/ml)-dissolved StemProSFM CTS (sup ⁇ , Life Technologies), 3) StemProSFM CTS (sup+, Life Technologies) and 4) PDGF-BB (10 ng/ml)-dissolved StemProSFM CTS (sup+, Life Technologies), as serum-free media (days 2, 4 and 7).
  • FIG. 9 is a photomicrograph of human skin fibroblasts cultured using 1) StemProSFM CTS (sup+, Life Technologies) and 2) PDGF-BB (10 ng/ml)-dissolved StemProSFM CTS (sup+, Life Technologies), as serum-free media, on days 2 and 7.
  • FIG. 10 is a graph showing changes in cell counts of human skin fibroblasts cultured using 1) StemProSFM CTS (sup+, Life Technologies) and 2) PDGF-BB (10 ng/ml)-dissolved StemProSFM CTS (sup+, Life Technologies), as serum-free media (days 2 and 7).
  • the present invention provides a serum-free medium for culturing of dermal sheath DS cells, the serum-free medium containing platelet-derived growth factor (PDGF) and particularly PDGF-BB, and to a method of culturing DS cells using the serum-free medium.
  • PDGF platelet-derived growth factor
  • Dermal sheath (DS) cells are a mesenchymal cell type present in the dermal sheath.
  • the dermal sheath (DS) also known as connective-tissue hair sheath or connective-tissue sheath, is the dermal tissue surrounding the epithelial outer root sheath.
  • DS cells are classified as mesenchymal cells, similar to hair papilla (dermal papilla, or DP) cells, with DP cells being thought to derive from DS cells.
  • the cells derived from the dermal sheath cup (DSC) region in particular which is the basal region near the hair papilla, proliferate before proliferation of DP cells during the hair growth cycle, and it is therefore believed that DS cells, and especially cells derived from the DSC region (also referred to as “DSC cells”) are the source of DP cells (Tobin D J et al., J. Invest. Dermatol., 120:895-904, 2003; NPL 4).
  • the dermal sheath, and especially the DSC region, is composed of a hetero cell group, and it is believed that these undergo descent with cell division and migration from the resting phase to the growth phase of the hair cycle, a portion thereof differentiating to hair papilla DP and initiating elongation of hair.
  • the DS cells of the invention can be obtained from the epidermis of various mammal such as humans, chimpanzees and other primates, livestock animals such as dogs, cats, rabbits, horses, sheep, goats, cows and pigs, and experimental animals such as rats, mice and guinea pigs, and more preferably nude mice, SCID mice and nude rats, but they are preferably human-derived cells, from the viewpoint of transplantation in humans and production of three-dimensional models for research.
  • the epidermal region may be a hairy region such as the scalp, or a hairless region such as the prepuce.
  • the DS cells may be cells obtained by primary culturing of tissue of the aforementioned mammals, or cells obtained from subculturing, or cells obtained by inducing differentiation from somatic stem cells, iPS cells or ES cells. From the viewpoint of conducting transplantation, cells grown by subculturing of cells obtained from the object of transplantation are preferred.
  • the basal medium that may be used for the invention is not particularly restricted so long as it is serum-free medium used for culturing of human or animal cells.
  • serum-free media include for example, HFDM-1(+) (Cell Science & Technology Institute), HFDM-1( ⁇ ) (Cell Science & Technology Institute), StemPro MSC SFM CTS (sup+) (Life Technologies), StemPro MSC SFM CTS (sup ⁇ ) (Life Technologies), Mosaic hMSC SF Culture Medium (sup+) (BD) and the like.
  • HFDM-1( ⁇ ) contains basal medium RITC80-7, 5 ⁇ g/ml, insulin and 10 ⁇ 7 M dexamethasone, and HFDM-1(+) contains, in addition to the above, 10 ng/ml EGF.
  • the serum-free medium of the invention contains platelet-derived growth factor (PDGF) as a growth factor for DS cells.
  • PDGF is a growth factor mainly involved in modulating migration and growth of mesenchymal cells (fibroblasts, smooth muscle cells, glial cells and the like), and it belongs to the PDGF/VEGF family. Being mainly produced by megakaryocytes, it is also present in platelet ⁇ -granules, and is known to be produced by various cells such as epithelial cells and endothelial cells.
  • PDGF-BB is particularly preferred among these.
  • the amount of PDGF added to the basal medium may be about 0.01 ng/ml to 10 ⁇ g/ml, preferably about 0.1 ng/ml to 100 ng/ml and more preferably about 1 to 10 ng/ml.
  • the serum-free medium of the invention may also contain an added Wnt signal activating agent.
  • the Wnt signal is a series of actions that promote nuclear localization of ⁇ -catenin and exhibit function as a transcription factor.
  • the signal includes a cascade due to intercellular interaction, when for example, the protein Wnt3A secreted from certain cells acts on other cells, causing nuclear localization of intracellular ⁇ -catenin, and leading to activity as a transcription factor.
  • the cascade brings about the initial phenomenon of organ assembly, of which epithelium mesenchymal interaction is a typical example.
  • the Wnt signal is known to control various cell functions such as cell motility during cellular growth and differentiation, organogenesis and early development, by activation of three pathways, the ⁇ -catenin pathway, PCP pathway and Ca 2+ pathway. It is utilized during culturing of ES cells, for the purpose of controlling differentiation, by the undifferentiated state-maintaining function of the Wnt signal (see Noburo Sato et al., Nature Medicine Vol. 10, No. 1, January 2004; NPL 5, for example).
  • any one exhibiting glycogen synthase kinase-3 (GSK-3) inhibitory activity may be used, examples of which include the bis-indolo(indirubin) compound (BIO) ((2′Z,3′E)-6-bromoindirubin-3′-oxime), its acetoxime analog BIO-acetoxime (2′Z, 3′E)-6-bromoindirubin-3′-acetoxime, the thiadiazolysine (TDZD) analog (4-benzyl-2-methyl-1,2,4-thiadiazolysine-3,5-dione), the oxothiadiazolysine-3-thione analog (2,4-dibenzyl-5-oxothiadiazolysine-3-thione), the thienyl- ⁇ -chloromethyl ketone compound (2-chloro-1-(4,4-dibromo-thiophen-2-yl)-ethan
  • the amount of addition of the Wnt signal activating agent may be any amount that leads to Wnt signal activation, or in other words, that produces GSK-3 inhibition and does not halt cell proliferation, which will depend on the type of chemical agent used and the type of cells to be grown, and may be appropriately determined by a person skilled in the art.
  • the amount may be, for example, about 0.01 ⁇ M to 100 ⁇ M, preferably 0.1 ⁇ M to 10 ⁇ M and more preferably about 10 ⁇ M.
  • the serum-free medium of the invention may contain added cell growth factors, hormones or other trace nutrients.
  • these include epithelial growth factor (EGF), tumor necrosis factor- ⁇ (TNF ⁇ ), hepatocyte growth factor (HGF), fibroblast growth factor 7 (FGF7), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factors ⁇ 1, 2, 3 (TGF ⁇ 1, 2, 3), bone morphogenetic protein (BMP) and insulin-like growth factor-1, 2 (IGF-1, 2), in which case the amounts may be about 0.1 ⁇ g/ml to 100 ⁇ g/ml, for example.
  • EGF epithelial growth factor
  • TNF ⁇ hepatocyte growth factor
  • FGF7 fibroblast growth factor 7
  • VEGF vascular endothelial growth factor
  • bFGF basic fibroblast growth factor
  • TGF ⁇ 1, 2, 3 transforming growth factors ⁇ 1, 2, 3
  • BMP bone morphogenetic protein
  • the amount may be about 0.1 ⁇ g/ml to 100 ⁇ g/ml, for example.
  • a fatty acid such as linolic acid, oleic acid or arachidonic acid
  • the amount may be about 0.001 ⁇ g/ml to 100 ⁇ g/ml, for example.
  • a prostaglandin is used, the amount may be about 0.1 ng/ml-100 ng/ml, for example.
  • the amount may be about 1 ⁇ g/ml to 100 ⁇ g/ml, for example.
  • a reducing agent such as ascorbic acid or reductive glutathione
  • the amount may be about 1 ⁇ g/ml to 100 ⁇ g/ml, for example.
  • mercaptoethanol the amount may be about 0.1 ⁇ g/ml to 100 ⁇ g/ml, for example.
  • transferrin or insulin the amount may be about 0.01 ⁇ g/ml to 100 ⁇ g/ml.
  • dexamethasone the amount may be about 0.000001 ⁇ M to 0.1 ⁇ M.
  • triiodothyronine the amount may be about 0.1 pM to 100 pM.
  • the amount When glucagon is used, the amount may be about 0.0001 ⁇ M to 0.1 ⁇ M. When cholesterol is used, the amount may be about 0.1 ⁇ g/ml to 100 ⁇ g/ml, for example. When hydrocortisone is used, the amount may be about 0.01 ⁇ g/ml to 10 ⁇ g/ml, for example. When testosterone is used, the amount may be about 0.1 ⁇ M to 100 ⁇ M, for example. When estradiol or progesterone is used, the amount may be about 0.01 ng/ml to 100 ng/ml, for example.
  • the amount may be about 0.000001 mg/ml to 0.1 mg/ml, for example.
  • a trace element for example, copper, zinc, cobalt, manganese, molybdenum or selenium
  • the amount may be about 0.1 ⁇ g/ml to 1000 ⁇ g/ml, for example.
  • Culturing of DS cells in such serum-free media is usually carried out using a culture dish set in an incubator at 37° C. in an atmosphere of 5% CO 2 , the culturing being continued (subculturing) after medium exchange upon confirming outgrowth.
  • the cultured cells obtained in this manner are further subcultured for the necessary passage number.
  • the subculturing may be carried out until the desired amount of DS cells is reached, and for example, 10 or more subculturings may be carried out, or if the desired amount is greater, preferably 15 or more and even more preferably 20 or more subculturings may be carried out.
  • the DS cells cultured in this manner are allowed to form a sphere (Japanese Unexamined Patent Publication HEI No. 7-274950; PTL 4).
  • Sphere formation produces cell growth to a saturated state, and after detachment of the cells, they are suspended in medium and the cell suspension is plated on medium in a non-adhesion-treated culture dish and allowed to stand for several days to form a cell aggregate consisting of a cell mass (spheroid).
  • the sphere formation is carried out in the absence of bFGF, although sufficient sphere formation can be achieved even in the presence of bFGF.
  • phase in which sphere formation is accomplished there are no particular restrictions on the phase in which sphere formation is accomplished, and it may be carried out on cultured cells that have passed through the final subculture.
  • Known culturing methods for formation of spheroids include roller bottle culturing, spinner flask culturing and hanging drop culturing, and culture vessels with recesses or culture vessels treated with low-cellular-adhesion coatings are commercially available. Also, by culturing using a culture vessel coated so that cell-adherent regions and non-cell-adherent regions are co-present, using a phosphorylcholine (PC)-based coating for the non-cell-adherent regions, it is possible to form large numbers of spheroids with consistent sizes.
  • PC phosphorylcholine
  • the sphericized DS cells prepared in this manner maintain hair follicle inducing ability and are therefore useful for in vitro experiments in research to elucidate the mechanisms of hair follicle reconstitution, or for hair regenerative medicine.
  • a 12-well plate (BD) was coated with CELLStartTM (Life Technologies), and cryopreserved DS cells (from 21-year-old male scalp, DSC, passage number: 0) were suspended in 1 ml of serum-free medium and seeded on the plate at 4 ⁇ 10 4 cells per well.
  • the serum-free media used were 1) HFDM-1( ⁇ ) medium (Cell Science & Technology Institute), 2) HFDM-1(+) medium (Cell Science & Technology Institute), 3) PDGF-AA (10 ng/ml)-dissolved HFDM-1( ⁇ ) medium and 4) PDGF-BB (10 ng/ml)-dissolved HFDM-1( ⁇ ) medium. Culturing was conducted at 37° C. in the presence of 5% carbon dioxide gas. The cells were observed under microscopy on days 2, 5 and 10 ( FIG. 1 : 40 ⁇ ), and the number of cells per visual field was counted ( FIG. 2 ).
  • a 12-well plate (BD) was coated with CELLStartTM (Life Technologies), and cryopreserved DS cells (from 50-year-old male scalp, DSC, passage number: 0) were suspended in 1 ml of serum-free medium and seeded on the plate at 4 ⁇ 10 4 cells per well.
  • the serum-free media used were 1) StemProSFM CTS (sup+, Life Technologies), 2) PDGF-BB (10 ng/ml)-dissolved StemProSFM CTS (sup+, Life Technologies) and 3) Mosaic hMSC SF Culture Medium (sup+, BD) and 4) PDGF-BB (10 ng/ml)-dissolved Mosaic hMSC SF Culture Medium (sup+, BD). Culturing was conducted at 37° C. in the presence of 5% carbon dioxide gas. The cells were observed under microscopy on days 2 and 7 ( FIG. 3 : 40 ⁇ ), and the number of cells per visual field was counted ( FIG. 4 ).
  • a 12-well plate (BD) was coated with CELLStartTM (Life Technologies), and cryopreserved DS cells (from 43-year-old male scalp, DS, passage number: 0) were suspended in 1 ml of serum-free medium and seeded on the plate at 4 ⁇ 10 4 cells per well.
  • the serum-free media used were 1) HFDM-1( ⁇ ) medium (Cell Science & Technology Institute), 2) HFDM-1(+) medium (Cell Science & Technology Institute), 3) PDGF-AA (10 ng/ml)-dissolved HFDM-1( ⁇ ) medium and 4) PDGF-BB (10 ng/ml)-dissolved HFDM-1( ⁇ ) medium. Culturing was conducted at 37° C. in the presence of 5% carbon dioxide gas. The cells were observed under microscopy on days 2, 4 and 7 ( FIG. 5 : 40 ⁇ ; 4th day not shown), and the number of cells per visual field was counted ( FIG. 6 ).
  • a 12-well plate (BD) was coated with CELLStartTM (Life Technologies), and cryopreserved DS cells (from 43-year-old male scalp, DS, passage number: 0) were suspended in 1 ml of serum-free medium and seeded on the plate at 4 ⁇ 10 4 cells per well.
  • the serum-free media used were 1) StemProSFM CTS (sup ⁇ , Life Technologies), 2) PDGF-BB (10 ng/ml)-dissolved StemProSFM CTS (sup ⁇ , Life Technologies), 3) StemProSFM CTS (sup+, Life Technologies) and 4) PDGF-BB (10 ng/ml)-dissolved StemProSFM CTS (sup+, Life Technologies). Culturing was conducted at 37° C. in the presence of 5% carbon dioxide gas. The cells were observed under microscopy on days 2, 4 and 7 ( FIG. 7 : 40 ⁇ ; 4th day not shown), and the number of cells per visual field was counted ( FIG. 8 ).
  • a 12-well plate (BD) was coated with CELLStartTM (Life Technologies), and cryopreserved human skin fibroblasts were suspended in 1 ml of serum-free medium and seeded on the plate at 4 ⁇ 10 4 cells per well.
  • the serum-free media used were 1) StemProSFM CTS (sup+, Life Technologies) and 2) PDGF-BB (10 ng/ml)-dissolved StemProSFM CTS (sup+, Life Technologies). Culturing was conducted at 37° C. in the presence of 5% carbon dioxide gas. The cells were observed under microscopy on days 2 and 7 ( FIG. 9 : 40 ⁇ ), and the number of cells per visual field was counted ( FIG. 10 ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US14/897,312 2013-06-12 2014-06-12 Serum-free medium containing pdgf for ds cells Abandoned US20160122714A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-123263 2013-06-12
JP2013123263 2013-06-12
PCT/JP2014/065599 WO2014200060A1 (ja) 2013-06-12 2014-06-12 Ｐｄｇｆを含有するｄｓ細胞用無血清培地

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/065599 A-371-Of-International WO2014200060A1 (ja) 2013-06-12 2014-06-12 Ｐｄｇｆを含有するｄｓ細胞用無血清培地

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/643,869 Division US11427807B2 (en) 2013-06-12 2017-07-07 Serum-free medium containing PDGF for DS cells

Publications (1)

Publication Number Publication Date
US20160122714A1 true US20160122714A1 (en) 2016-05-05

Family

ID=52022346

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/897,312 Abandoned US20160122714A1 (en) 2013-06-12 2014-06-12 Serum-free medium containing pdgf for ds cells
US15/643,869 Active 2034-08-30 US11427807B2 (en) 2013-06-12 2017-07-07 Serum-free medium containing PDGF for DS cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/643,869 Active 2034-08-30 US11427807B2 (en) 2013-06-12 2017-07-07 Serum-free medium containing PDGF for DS cells

Country Status (9)

Country Link
US (2) US20160122714A1 (zh)
EP (1) EP3009503B1 (zh)
JP (1) JP6502255B2 (zh)
KR (2) KR102347062B1 (zh)
CN (1) CN105452441B (zh)
CA (1) CA2917684C (zh)
SG (2) SG10201710303TA (zh)
TW (1) TWI666320B (zh)
WO (1) WO2014200060A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105713873A (zh) * 2016-04-20 2016-06-29 广东艾时代生物科技有限责任公司 一种免疫细胞体外扩增培养的无血清培养基及其应用
CN106434549A (zh) * 2016-12-20 2017-02-22 江西宜信堂医疗科技有限公司 一种无血清干细胞培养基及其制备方法
KR102331564B1 (ko) * 2017-02-09 2021-11-26 가톨릭대학교 산학협력단 이종 동물 혈청이 첨가된 배지 없이 사람 하비갑개 유래 중간엽 줄기세포를 배양 및 분화시키는 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635589B2 (en) * 2004-11-29 2009-12-22 Lifecord Inc., Corp. Method for the preparation of a dermal papilla tissue having hair follicle inductive potency

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3573488B2 (ja) 1994-04-11 2004-10-06 独立行政法人 科学技術振興機構 毛乳頭細胞の長期継代培養法
KR20030043313A (ko) * 2001-11-27 2003-06-02 한스바이오메드 주식회사 사람 각질세포 및 성장인자가 함유된 피브린 접착제를주재로 한 피부재생촉진제 및 그의 제조방법
JP2005515777A (ja) * 2002-01-25 2005-06-02 ジェンザイム・コーポレーション 軟骨細胞のための無血清培地およびその使用法
DE10224982A1 (de) * 2002-06-05 2003-12-24 Rolf Hoffmann Mesenchymale Stammzellen des Haarfollikels und deren Verwendung
KR100834731B1 (ko) * 2003-01-07 2008-06-13 주식회사 바이오랜드 세포 배양에 대한 기질 또는 기저막으로서 양막의 이용과이를 이용한 세포 치료제로서의 제조 방법 및 이의 용도
JP4200081B2 (ja) 2003-11-17 2008-12-24 ヤマハリビングテック株式会社 スピーカシステム並びに浴室ユニット
JP2005218445A (ja) * 2004-01-09 2005-08-18 Technology Seed Incubation Co Ltd 培養皮膚細胞とこれを原料として用いた移植用材及び遺伝子解析用材並びに培養皮膚細胞の製造方法
JP4804031B2 (ja) 2005-05-09 2011-10-26 オリンパス株式会社 間葉系幹細胞の培養方法および生体組織補填体の製造方法
JP2006325445A (ja) 2005-05-24 2006-12-07 Toyobo Co Ltd 間葉系幹細胞増殖培地
WO2007037486A1 (ja) * 2005-09-30 2007-04-05 Phoenixbio Co., Ltd. 毛包真皮毛根鞘細胞の培養法
US20070212335A1 (en) * 2006-03-07 2007-09-13 Hantash Basil M Treatment of alopecia by micropore delivery of stem cells
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
JP5300273B2 (ja) 2008-01-21 2013-09-25 株式会社 資生堂 ヒトＷｎｔ３ａ遺伝子形質転換細胞
CN103068969A (zh) * 2010-06-17 2013-04-24 思迪公司 化学成分确定的无血清细胞培养基
JP5933443B2 (ja) * 2010-09-17 2016-06-08 株式会社 資生堂 Ｐｄｇｆ−ｂｂ活性亢進による皮膚賦活化
KR20130055274A (ko) * 2011-11-18 2013-05-28 부경대학교 산학협력단 해초 추출물을 유효성분으로 함유하는 모발 증식 및 생장 촉진용 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635589B2 (en) * 2004-11-29 2009-12-22 Lifecord Inc., Corp. Method for the preparation of a dermal papilla tissue having hair follicle inductive potency

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kamp, H. et al. 2003. Regulation of PDGF and PDGF receptor in cultured dermal papilla cells and follicular keratinocytes of the human hair follicle. Experimental Dermatology 12: 662-672. specif. pp. 663, 664, 669 *

Also Published As

Publication number Publication date
EP3009503A1 (en) 2016-04-20
JP6502255B2 (ja) 2019-04-17
KR20200145851A (ko) 2020-12-30
CN105452441B (zh) 2021-01-01
US20170313982A1 (en) 2017-11-02
JPWO2014200060A1 (ja) 2017-02-23
KR20160018668A (ko) 2016-02-17
EP3009503A4 (en) 2016-10-26
CA2917684A1 (en) 2014-12-18
CA2917684C (en) 2021-07-20
SG11201510040VA (en) 2016-01-28
TWI666320B (zh) 2019-07-21
SG10201710303TA (en) 2018-02-27
WO2014200060A1 (ja) 2014-12-18
US11427807B2 (en) 2022-08-30
KR102347062B1 (ko) 2022-01-03
TW201522635A (zh) 2015-06-16
EP3009503B1 (en) 2019-08-07
CN105452441A (zh) 2016-03-30

Similar Documents

Publication Publication Date Title
JP5227024B2 (ja) 毛包真皮毛根鞘細胞の培養法
US9764064B2 (en) Methods for producing hair microfollicles and de novo papillae and their use for in vitro tests and in vivo implantations
US8563309B2 (en) Primitive organ-like structure comprising keratinocytes and hair papilla cells
KR20110022713A (ko) 인간 만능줄기세포로부터 인간 피부 대체물을 제조하는 방법
US11427807B2 (en) Serum-free medium containing PDGF for DS cells
US20240084249A1 (en) Composition and method for generating a desired cell type and/or tissue type from hair follicular stem cells
JP5258213B2 (ja) 体性に由来する複数の細胞種からなる原始的な器官様をなし得る細胞塊
JP2007274949A (ja) 毛乳頭細胞培養方法
JP5164439B2 (ja) 毛乳頭細胞培養方法
JP5301146B2 (ja) 特定の方法で培養されたケラチノサイト前駆細胞及びその製造方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: SHISEIDO COMPANY, LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YAMANISHI, HARUYO;SOMA, TSUTOMU;YOSHIDA, YUZO;REEL/FRAME:037452/0414

Effective date: 20151229

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION